A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products
- PMID: 27604324
- PMCID: PMC5069709
- DOI: 10.1089/hgtb.2016.044
A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products
Erratum in
-
Correction to: Hum Gene Ther Methods 2016;27(5):187-196.Hum Gene Ther Methods. 2017 Feb;28(1):60. doi: 10.1089/hgtb.2016.044.correx. Epub 2017 Jan 31. Hum Gene Ther Methods. 2017. PMID: 28140663 Free PMC article. No abstract available.
Abstract
Adenovirus (Ad) is used extensively for construction of viral vectors, most commonly with deletion in its E1 and/or E3 genomic regions. Previously, our attempts to insert envelope proteins (Env) of HIV-1 into such vectors based on chimpanzee-derived Ad (AdC) viruses were thwarted. Here, we describe that genetic instability of an E1- and E3-deleted AdC vector of serotype C6 expressing Env of HIV-1 can be overcome by reinsertion of E3 sequences with anti-apoptotic activities. This partial E3 deletion presumably delays premature death of HEK-293 packaging cell lines due to Env-induced cell apoptosis. The same partial E3 deletion also allows for the generation of stable glycoprotein 140 (gp140)- and gp160-expressing Ad vectors based on AdC7, a distinct AdC serotype. Env-expressing AdC vectors containing the partial E3 deletion are genetically stable upon serial cell culture passaging, produce yields comparable to those of other AdC vectors, and induce transgene product-specific antibody responses in mice. A partial E3 deletion thereby allows expansion of the repertoire of transgenes that can be expressed by Ad vectors.
Keywords: HIV-1; genetic stability; immune responses; vaccine.
Conflict of interest statement
Author Disclosure No competing financial interests exist.
Figures






References
-
- Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999;10:440–447 - PubMed
-
- Appaiahgari MB, Vrati S. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther 2015;15:337–351 - PubMed
-
- Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004;15:1157–66 - PubMed
-
- Hensley SE, Giles-Davis W, McCoy KC, et al. . Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol 2005;175:6032–6041 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous